← Back to news

G

Google Business, RSS Feed

No Fed rate move expected as Powell-Warsh shift looms. What to know - USA Today

Stock market today: Dow, S&P 500, Nasdaq slip to start pivotal week as markets weigh Iran peace odds - Yahoo Finance

Chevron CEO warns aviation strain could worsen as jet fuel crunch deepens - Fox Business

Why Is POET Technologies Stock Down Today? - TipRanks

Wall Street indexes enter earnings-heavy week on cautious footing - Reuters

Carney to Create Canadian Sovereign Wealth Fund to Back Projects - Bloomberg.com

The ‘wizards’ behind the online version of Magic: the Gathering are unionizing - The Guardian

Elon Musk and Sam Altman face off in court over OpenAI’s founding mission - The Guardian

Social Security benefits can be reduced for some retirees who work. How that may change - CNBC

Elon Musk Registers 304 Million Tesla Shares. Stock Sinks. - Investor's Business Daily

Shell to acquire Canada's ARC in output-boosting $16.4 billion deal - Reuters

Jain Global to Return Cash, Exclusively Manage Millennium Money - Bloomberg.com

Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion - Reuters

OpenAI could be making a phone with AI agents replacing apps - TechCrunch

The market is acting like the war in Iran is a non-factor - investingLive

The next phase of the Microsoft OpenAI partnership - OpenAI

POET Technologies Provides Purchase Order Update - Stock Titan

OpenAI shakes up partnership with Microsoft, capping revenue share - CNBC

POET Technologies stock tumbles after losing Marvell orders - Investing.com

POET Technologies Provides Purchase Order Update - GlobeNewswire

How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise - Investor's Business Daily

Dow Set to Open Little Changed Ahead of Busy Week for Markets - Barron's

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Micron, AMD, DoorDash, CrowdStrike & more - CNBC

United Airlines Says It Pitched American on Merger but Was Rebuffed - The New York Times

Oil giant Shell to buy Canada’s ARC Resources for $16.4 billion in push to boost output - CNBC

Stock Market Today: Dow Firm As Pharma Stocks Shine; Nvidia Nears Record Highs (Live Coverage) - Investor's Business Daily

DeepSeek's new AI model does not wow markets in fast-changing industry - Reuters

This bank CEO let his AI clone handle an earnings call — now he's signing an OpenAI deal - CNBC

Spotify’s next frontier: fitness content - TechCrunch

China orders Meta to unwind $2 billion purchase of AI startup Manus - Reuters

Stock Market Today: Dow, S&P 500 Move Higher; Oil Climbs — Live Updates - WSJ

U.S.-Iran talks stall; earnings frenzy ahead - what’s moving markets - Investing.com

United chief hits out at American Airlines for refusing merger talks - Financial Times

The bullish signals ahead of this week's Mag-7 earnings - CNBC

Wall Street expects solid Q1 results for GM, as Ford and Stellantis try to gain traction - CNBC

Taiwan court sentences ex-Tokyo Electron staff to 10 years in TSMC trade secrets case - AP News

Ford's Mustang Cobra Jet sets a new EV quarter mile record at 6.87 seconds - Engadget

Exclusive | Re/Max Nears Sale to Tech-Focused Real-Estate Firm - WSJ

Dwarkesh! - Marginal REVOLUTION

MAHA at odds with Trump over Supreme Court's glyphosate case, farm bill - CNBC

Maryland moves to ban surveillance pricing in grocery stores - Fox News

Stocks Ride Record Semis Run Ahead of Big Tech Earnings. There’s Little Room for Error. - Barron's

China says it will reverse major AI acquisition by Meta - The Washington Post

United Airlines CEO confirms he approached American Airlines about merger - CNBC

Canada Says Its Gold Is Traceable and Clean. So We Traced It. - The New York Times

Fed likely to hold rates steady as Powell prepares for possible swan song - Reuters

Verizon lifts annual profit forecast after surprise rise in wireless subscribers - Yahoo Finance

Veradermics’ hair loss drug succeeds in late-stage trial | STAT - statnews.com

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial - CNBC